

### **ASX ANNOUNCEMENT**

# **Results of Annual General Meeting**

**Sydney, 28 November 2018: Actinogen Medical (ASX: ACW)** advises that the Company held its Annual General Meeting today, 28 November 2018 at 11.30 am (AEDT).

The resolutions voted were in accordance with the Notice of Annual General Meeting previously advised to the Australian Securities Exchange.

Further information, required by Section 251AA(2) of the Corporations Act 2001 (Cth), is attached.

Yours faithfully

**Peter Webse** 

**Company Secretary** 

**ENDS** 

### **About Actinogen Medical**

Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Actinogen Medical is developing its lead compound Xanamem, as a promising new therapy for Alzheimer's disease, a condition with a multibillion-dollar market potential. In the US alone, the cost of managing Alzheimer's disease is estimated to be US\$250bn, and is set to increase to US\$2tn by 2050, outstripping the treatment costs of all other diseases. Alzheimer's disease is now the leading cause of death in the UK and second only to ischaemic heart disease in Australia

#### **About Xanamem™**


Xanamem's novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol - the stress hormone – through the inhibition of the  $11\beta$ -HSD1 enzyme in the brain. This enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease. There is a strong association between chronic stress and excess cortisol that leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death – all hallmarks of Alzheimer's disease.

#### **About XanADu**

XanADu is a Phase II double-blind, 12-week, randomised, placebo-controlled study to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's disease. XanADu has fully enrolled 186 patients from 25 research sites across Australia, the UK and the USA. Results are expected in Q2 2019. The trial is registered on www.clinicaltrials.gov with the identifier: NCT02727699, where more details on the trial can be found, including the study design, patient eligibility criteria and the locations of the study sites.

Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.

## **ACTINOGEN MEDICAL LIMITED**





ANNUAL GENERAL MEETING Wednesday, 28 November, 2018

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

		Manner in which the (as at proxy close):	•	ected the proxy vote	Manner in which votes were cast in person or by proxy on a poll (where applicable)			
Res	olution	Votes <b>For</b>	Votes <b>Against</b>	Votes Discretionary	Votes <i>Abstain</i>	For	Against	Abstain **
1	ADOPTION OF REMUNERATION REPORT	529,969,419	16,253,320	21,832,999	1,439,315	Passed on a show of hands	Passed on a show of hands	Passed on a show of hands
2	APPROVAL OF 10% PLACEMENT FACILITY	560,162,371	13,580,017	34,649,393	1,621,244	Passed on a show of hands	Passed on a show of hands	Passed on a show of hands
3	RE-ELECTION OF DIRECTOR - DR GEORGE MORSTYN	573,180,044	658,844	34,533,393	1,640,744	Passed on a show of hands	Passed on a show of hands	Passed on a show of hands
4	RATIFICATION OF PLACEMENT UNDER LISTING RULE 7.1 CAPACITY	560,847,277	12,691,403	34,697,286	1,777,059	Passed on a show of hands	Passed on a show of hands	Passed on a show of hands
5	AUTHORITY TO GRANT DIRECTOR OPTIONS TO DR GEOFF BROOKE	537,873,319	36,242,212	34,535,494	1,362,000	Passed on a show of hands	Passed on a show of hands	Passed on a show of hands
6	AUTHORITY TO GRANT DIRECTOR OPTIONS TO DR BILL KETELBEY	539,350,134	36,090,397	21,892,600	37,000	Passed on a show of hands	Passed on a show of hands	Passed on a show of hands
7	AUTHORITY TO GRANT DIRECTOR OPTIONS TO DR GEORGE MORSTYN	539,158,319	36,090,397	34,727,309	37,000	Passed on a show of hands	Passed on a show of hands	Passed on a show of hands
8	RENEWAL OF EMPLOYEE OPTION PLAN	506,379,741	34,455,897	27,271,915	1,387,500	Passed on a show of hands	Passed on a show of hands	Passed on a show of hands

<sup>\*\* -</sup> Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item

## **ACTINOGEN MEDICAL LIMITED**





ANNUAL GENERAL MEETING Wednesday, 28 November, 2018

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

	Manner in which the securityholder directed the proxy vote (as at proxy close):				Manner in which votes were cast in person or by proxy on a poll (where applicable)		
Resolution	Votes <b>For</b>	Votes <b>Against</b>	Votes <b>Discretionary</b>	Votes <i>Abstain</i>	For	Against	Abstain **
9 SECTION 195 APPROVAL	547,588,201	12,978,202	46,217,997	3,228,625	Passed on a show of hands	Passed on a show of hands	Passed on a show of hands

<sup>\*\* -</sup> Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item